GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » EPS (Diluted)

Renalytix (Renalytix) EPS (Diluted) : $-0.78 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Renalytix EPS (Diluted)?

Renalytix's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.16. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.78.

Renalytix's EPS (Basic) for the three months ended in Mar. 2024 was $-0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.78.

Renalytix's EPS without NRI for the three months ended in Mar. 2024 was $-0.13. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.68.

During the past 3 years, the average EPS without NRIGrowth Rate was -42.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Renalytix's highest 3-Year average EPS without NRI Growth Rate was 12.30% per year. The lowest was -42.40% per year. And the median was -15.05% per year.


Renalytix EPS (Diluted) Historical Data

The historical data trend for Renalytix's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix EPS (Diluted) Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EPS (Diluted)
Get a 7-Day Free Trial -1.98 -0.34 -0.86 -1.34 -1.10

Renalytix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.22 -0.22 -0.18 -0.16

Competitive Comparison of Renalytix's EPS (Diluted)

For the Health Information Services subindustry, Renalytix's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's PE Ratio distribution charts can be found below:

* The bar in red indicates where Renalytix's PE Ratio falls into.



Renalytix EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Renalytix's Diluted EPS for the fiscal year that ended in Jun. 2023 is calculated as

Diluted EPS (A: Jun. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-45.607-0)/41.105
=-1.11

Renalytix's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-7.743-0)/48.827
=-0.16

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix  (NAS:RNLX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Renalytix EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Renalytix's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix (Renalytix) Business Description

Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Executives
Howard Jr Doran officer: Chief Business Officer C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain officer: President NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc. 10 percent owner 150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills director, 10 percent owner C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling officer: Chief Financial Officer C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc. 10 percent owner ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount 10 percent owner ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming director, officer: Chief Technical Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough director, officer: Chief Executive Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE

Renalytix (Renalytix) Headlines

From GuruFocus

Renalytix announces a c.$20.3 million private placement

By Stock market mentor Stock market mentor 02-08-2023